Clinical Outcomes Observed among Biopsy Proven Lupus Nephritis Patients Treated with Mycophenolate Mofetil as First-line Therapy

Background and objective The rate of end-stage renal disease from lupus nephritis has not declined, in spite of recent advances in therapeutics, such as mycophenolate mofetil (MMF). To provide insight into rates of the clinical outcomes in current practice after biopsy-proven lupus nephritis, we use...

Descripción completa

Detalles Bibliográficos
Autores principales: Timlin, Homa, Magder, Laurence, Petri, Michelle
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2017
Materias:
Allergy/Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5796813/
https://www.ncbi.nlm.nih.gov/pubmed/29410944
http://dx.doi.org/10.7759/cureus.1907

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5796813/
https://www.ncbi.nlm.nih.gov/pubmed/29410944
http://dx.doi.org/10.7759/cureus.1907

Ejemplares similares